EXELIXIS INC (EXEL.OQ) Trading
Live Chart & Price Analysis
View the real-time EXELIXIS INC (EXEL.OQ) quote and decide if you want to go long or short. Find insights, analysis, the latest news and other information to help you with your trading.
$64.58
-0.98%Followers
6
Annual change
67.26%
Daily price range:
Low
63.78
High
64.92
Trade EXEL
CFD trading involves risk
EXEL live price
Live Chart
Past performance is not a reliable indicator of future results.
Should you buy or sell EXELIXIS INC right now?
Based on NAGA Sentiment¹, 100.00% are buying EXELIXIS INC and 0.00% are selling EXELIXIS INC right now. However, opening a long or short position now depends on your risk tolerance, investment horizon, and EXELIXIS INC market outlook.
Selling
0.00%
100.00%
Buying
EXELIXIS INC price analysis
The price of EXELIXIS INC today, as of October 23, 2026, was $64.58. That's down -0.10% from last session's EXELIXIS INC closing price. The EXELIXIS INC price is rising this week. Compared to last week, the rate of EXELIXIS INC is up 2.90%, and it's up 11.30% from one month ago.
The 52-week EXELIXIS INC price high is $65.38, while the 52-week EXELIXIS INC price low is $36.28.
Year to date, EXELIXIS INC price is up 67.00% from the beginning of the year and has had a return of 67.00% in the last 12 months.
Low$63.78
Day's Range
Low$36.28
52w Range-0.1%
1h
-0.1%
24h
+2.9%
7d
+9.4%
14d
+11.3%
30d
+67.0%
1y
EXELIXIS INC trading insights
The crowd feels POSITIVE about EXELIXIS INC, with a LOW volume of news backing the POSITIVE sentiment score². At the start of today's EXELIXIS INC trading session, the sentiment signal³ is BULLISH, indicating whether the EXELIXIS INC price is more likely to increase or decrease today and in the following days.
The level of news⁴ backing the sentiment score is LOW, indicating how confident the markets are to buy EXELIXIS INC right now. The LOW subjectivity⁵ indicates that the EXELIXIS INC price is UNDERVALUED.
Sentiment Signal
Bullish
Next update: Oct 26, 12:30
Sentiment Score
Positive
71 / 100
Subjectivity
Low Subjectivity
29 / 100
Confidence Index
Low
Discover key EXELIXIS INC trends with NAGA Insights
What am I Missing?
Make informed decisions based on real-time data, expert analysis, and powerful research tools from TipRanks.
Access advanced EXELIXIS INC charting, technical analysis, and live market data from TradingView.
Get AI-powered EXELIXIS INC trade signals, in-depth market analysis, and technical strategy insights from Trading Central.
CFD trading involves risk
How to trade EXELIXIS INC with leverage?
Trade EXELIXIS INC if you want flexibility to speculate on its price movements in both directions. With CFDs, you can open a buy position (go long) if you think the EXELIXIS INC price will rise, or you can open a sell position (go short) if you believe the EXELIXIS INC price will fall.
You won’t need to commit to the full value of the position (see the required margin below), but bear in mind that leverage can increase both your profits and losses.
If you want to speculate on EXELIXIS INC price, search for EXELIXIS INC CFD. Then click on the "EXELIXIS INC" symbol to view the chart and other insights before placing your trade. Also, review "EXELIXIS INC" contract specification to be aware of all the EXELIXIS INC CFD trading conditions.
trading conditions:
Platform
MT5
Platform spreads
Live: 0.1964
Ticker#EXEL.OQ
Margin (%)*
Volume step
Lot value
Minimum trade size
Maximum trade size
Commission0.00%
Monthly price change (%)11.15%
Annual price change (%)67.26%
Digits
Tick value0.009
Trading Hours & FeesCFD trading involves risk
About EXELIXIS INC
EXEL
Exelixis Inc
CFD
-0.98%
$64.8
$64.58
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
EXELIXIS INC price forecast, news, and analysis
Discover the latest news that can influence EXELIXIS INC’s earnings sentiment and EXELIXIS INC forecast and price predictions.
Neutral
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
22/10/2026/09:00
FAQs about EXELIXIS INC trading
The price of EXELIXIS INC today, as of October 23, 2026, was 64.58. That's down -0.10% from the previous session's EXELIXIS INC closing price.
IMPORTANT NOTICE: The content presented in the instrument page is only for informational, educational and support purposes. The material presented, including analyses, sentiment, consensus, prices, opinions or other content, is not an investment recommendation or information that recommends or suggests an investment strategy, nor is it included in the scope of investment advice. NAGA will not accept liability for any loss or damage, including but not limited to any loss of profits, that may arise directly or indirectly from the use of or reliance on the information contained in this page. NAGA is not responsible for the actions or omissions of the client, especially for the acquisition or disposal of financial instruments, made based on the information contained in this page. Past performance is not necessarily indicative of future results, and anyone acting on this information does so at their own risk. ¹ NAGA sentiment reflects the positions held by active NAGA users who currently maintain open trades in a specific instrument. This information is provided for indicative purposes only and should not be interpreted as investment advice or a recommendation to trade. ² ³ ⁴ ⁵ The sentiment dashboard is provided by Trading Central. Sentiment insights and market views are based on available data and do not guarantee future performance.
Need Help? Visit our Help Section
Download NAGA Trader
Download NAGA Trader
Click the QR code to enlarge
Copyright © 2026 – All rights reserved.
NAGA is a trademark of The NAGA Group AG, a German based FinTech company publicly listed on the Frankfurt Stock Exchange | WKN: A41YCM | ISIN: DE000A41YCM0.
The website is operated by JME Financial Services (Pty) Ltd an authorised Financial Services Provider, regulated by the Financial Sector Conduct Authority in South Africa under license no. 37166. JME Financial Services (Pty) Ltd is located at Suite 10, 21 Lighthouse Rd 201 Beacon Rock, Umhlanga Rocks, Kwa-Zulu Natal, 4320, South Africa.
JME Financial Services (Pty) Ltd acts as an intermediary between the investor and NAGA Capital Ltd, the counterparty to the contract for difference purchased by the Investor via Naga.com/za. NAGA Capital Ltd is authorised and regulated by the Financial Services Authority Seychelles (FSA) under licence No. SD026. NAGA Capital Ltd is the principal to the CFD purchased by investors on this website. Other group entities: NAGA Markets Europe LTD which is authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC) under licence No. 204/13.
RISK WARNING: Derivatives are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how derivatives work and whether you can afford to take the high risk of losing your money. The value of financial products can increase as well as decrease over time, depending on the value of the underlying securities and market conditions. Illustrations, forecasts or hypothetical data are not guaranteed and are provided for illustrative purposes only. JME Financial Services (Pty) Ltd does not render advice in respect of the CFD’s offered on this website. Before making an investment decision, you should rely on your own assessment. The Company’s disclaimer, conflict of interest policy are available on legal documents section.